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Inadequacy of antiretroviral
drugs dosage adjustment in
HIV patients receiving dialysis
Letter to the Editor: Szczech et al [1] reported an
interesting study in a recent issue of Kidney International.
The authors reported the antiretroviral drugs dosing reg-
imens they observed in their hemodialyzed patients. We
further analyzed these dosing regimens and it appeared
that dosage adjustement were most often inadequate for
those patients with end-stage renal disease.
Table 1. Comparison of antiretroviral dosage reported in Szczech’s
study and available dosing recommendations for hemodialysis
patients [2]
Recommended
Drug N Dosage dosage
Nucleoside reverse transcriptase inhibitors
Abacavira 3 300 to 600 mg/day 1200 mg/day
Didanosine 7 100 to 400 mg/day 50 to 100 mg/day
Lamivudine 36 25 to 300 mg/day 150 mg first dose then
25 to 50 mg/day
Stavudine 33 10 to 40 mg/day 15 to 20 mg/day
Zidovudine 11 100 mg 3 × a week 300 mg/day
to 600 mg/day
Combivir 8
Lamivudine 150 to 450 mg/day 150 mg first dose then
25 to 50 mg/day
Zidovudine 300 to 900 mg/day 300 mg/day
Non-nucleoside reverse transcriptase inhibitors
Efavirenza 13 200 to 600 mg/day 600 mg/day
Nevirapinea 11 200 to 400 mg/day 200 to 400 mg/day
Protease inhibitors
Indinavira 6 1600 to 2400 mg/day 2400 mg/day
Nelfinavira 21 500 to 2500 mg/day 2250 mg/day
Ritonavira 5 200 to 1000 mg/day 1200 mg/day
Saquinavira 2 800 to 3600 mg/day 1800 mg/day
N = Number of patients in Szczech’s study.
Combivir, 1 capsule contains 150 mg lamivudine and 300 mg zidovudine.
aDrug for which dosage adjustment is not necessary in hemodialyzed patients.
We read with great interest Szczech’s article [1], in
which they concluded that antiretroviral medications
were not used at their optimal dose in the human
immunodeficiency virus (HIV) hemodialysis patients
they studied because data on these drugs’ pharmacoki-
netics and dosage adjustment in patients with renal insuf-
ficiency are lacking. However, we would like to outline
that most antiretroviral drugs’ pharmacokinetics have
been studied in patients with renal insufficiency.
Based on those publications and our personal data, we
have recently published precise guidelines on antiretro-
viral drug dosage adjustment in hemodialysis patients [2].
Among the 11 antiretroviral drugs reported in Szczech’s
article, only 1 was administered at the correct dose (nevi-
rapine). The other drugs that should have been prescribed
at their usual dosage were either underdosed (abacavir,
efavirenz, indinavir, nelfinavir, ritonavir, saquinavir) or
overdosed (saquinavir). For the latter, the usual recom-
mended dose for hemodialysis patients is 1800 mg/day
[2]; the dosing range reported by Szczech is 800 to
3600 mg/day. Among the drugs that should have had their
dose adjusted according to the patients’ renal function,
didanosine was clearly overdosed. Stavudine, lamivudine,
and zidovudine administered alone were either under- or
overdosed. Finally, the use of the lamivudine-zidovudine
combination drug Combivir led to a large overdose in
all cases.
Consequently, although we agree that further pharma-
cokinetic, tolerance, and efficacy studies are mandatory
for these patients, dose adjustment recommendations
exist [2] and should already be routinely applied.
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Calcimetic AMG 073 at 50
and 100 mg per day
To the Editor: A comparison of the assessment against
placebo of the calcimimetic AMG 073 at 50 [1] and
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Table 1. Comparison of calcium-mimetic AMG 073 at 50 and 100 mg/day
Lindberg (KI 2003;63:248) Quarles (JASN 2003;14:575)
AMG 50 mg Placebo AMG 100 mg Placebo
Patients Nb:total No. at maximum maintenance dose 34 (21) 34 31 (17) 31
Ca-PO4 binder Ca element mg/day No change No change −2 +294
Sevelamer mg/day None None −111 +163
Calcitriol/paricalcitol dose change lg/wk None None −0.9/−6.5 −1.3/−7
Introduction of calcitrol or paricalcitol No. patients – – 10/4 3/4
Changes at maintenance period versus baseline %
SCa −4.7b 0 −4.6b +2.6
SPO4 −7.5b +11 −2.6 NS +7
SCa × SPO4 −12b +11 −7.9a +11
PTH −26b +22 −32b −3
PTH absolute value baseline/maintenance 637/460 632/701 626/451 583/552
PTH absolute change pg/mL −177 +69 −175 −31
PTH, parathyroid hormone.
aP < 0.01.
bP < 0.003.
100 mg/day [2], surprisingly, shows no obvious better re-
sults in parathyroid hormone (PTH) suppression (−26 vs.
−32%) or in Ca × PO4 product control (−12 vs. −7.9%).
Although the two calcium mimetic–treated groups were
not randomized, they had comparable baseline charac-
teristics regarding serum concentration of PTH, Ca and
PO4, and use of vitamin D and phosphate binder. Regard-
ing concomittant therapy change differences between
active and placebo-treated groups, stability in both PO4
binder and vitamin D was documented only in the 50 mg
study. Indeed, in the 100 mg study, although weekly doses
of calcitriol and paracalcitol were the same in both groups,
the vitamin D treatment had to be started in 14 patients
receiving AMG 073 versus only 7 in patients receiving
placebo. This higher incidence of new vitamin D treate-
ment in the 100 mg titrated group explains that, in spite of
this twice higher dose, the decrease of serum calcium was
comparable in both studies (−4.6 and −4.7%), whereas
the decrease of serum phosphate was more than twice
smaller (−2.6 vs. −7%) and not significantly different
from the control group as it was in the 50 mg study
(Table 1). Indeed, calcitriol is known to increase active
intestinal absorption of both calcium and phosphate on
an equimolar basis [3].
We suggest, therefore, that correcting the hypocal-
cemic effect of the calcimimetic by increasing calcium-
phosphate binder rather than introducing calcitriol would
be more efficient to decrease serum phosphate for the
same decrease in PTH as shown by a randomized
study [4].
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Vitamin C improves vascular
resistance in patients with
chronic renal failure
To the Editor: Vitamin C, an antioxidant, has been
widely used as a free radical scavenger. In a recent is-
sue of Kidney International, the article by Cross et al [1]
concluded that acute parental administration of ascor-
bic acid reduced oxidant stress and improved nitric oxide
(NO)-mediated resistance vessel dilatation in uremic pa-
tients. However, they also revealed significantly increased
lipid hydroperoxides. Ascorbic acid could exert its pro-
oxidant effect through Fenton chemistry to generate free
radicals [2]. In our recent study, the increased generation
of superoxide detected by leucigenin-enhanced chemilu-
minescence was noted following bolus administration of
ascorbic acid 300 mg at the end of the hemodialysis (HD)
session (Fig. 1). The pro-oxidant effect of bolus injection
of ascorbic acid is especially evident in iron-overloaded
uremic patients [3]. Currently, many dialysis patients are
treated with intravenous iron and may have received
multiple blood transfusions. Consequently, some may be-
come iron overloaded. Without monitoring iron indices,
